France· FR:63918096
AZACTAM 1 g, poudre pour solution injectable/pour perfusion
A aztreonam product containing aztréonam, registered in France by LABORATOIRES DELBERT, on the national reimbursement list. The same ATC class is registered in 16 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Aztreonam is registered in 16 of 19 countries.
Countries holding a registration under ATC J01DF01 (aztreonam), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 10 of them publish a price we can compare per daily dose
Aztreonam · ATC J01DF01
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of aztreonam costs, country by country.
Normalised to the WHO defined daily dose (0.225 g), the median price runs from $4.80 in Spain to $107.66 in Switzerland — a ×22 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Aztreonam · price per daily dose (0.225 g)
USD · FX 28 Sept 2026
- CH Switzerland$107.66
- ES Spain$4.80
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- AZTRÉONAM
- Manufacturer
- LABORATOIRES DELBERT
- Country
- France (FR)
- ATC code
- J01DF01
- ATC class
- Aztreonam
- Defined daily dose
- 0.225 g, Inhal
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip1334009369208591 flacon(s) en verreEUR 26.66
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
40 interactions on record for aztreonam.
Graded by severity as the source publishes them — 10 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Aztreonam · interactions on record
40 records
- 10 moderate
- 30 info
Most severe, free to view
- Sodium picosulfateA06AB08moderate
- DicoumarolB01AA01moderate
- WarfarinB01AA03moderate
- Levonorgestrel and ethinylestradiolG03AA07moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Aztreonam in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesAZACTAME.R. Squibb & Sons, L.L.C.
- United KingdomAzactam 1g powder for solution for injection vialsKent Pharma (UK) Ltd
- IrelandAzactam 1 g Powder for Solution for Injection or InfusionAthlone Pharmaceuticals Limited
- BelgiumAzactam 1 gLaboratoires Delbert
- FinlandAzactamLaboratoires Delbert x
- SwitzerlandAzactam 2 g, poudre pour solution injectable/pour perfusionLeman SKL SA
- SpainAZACTAM 1g POLVO PARA SOLUCION INYECTABLEGalenicum Derma S.L.U.
- NorwayAzactamLaboratoires Delbert
Authorised across Europe · EMA
The same active substance is authorised in 13 EEA countries. Names it is sold under:
- Austria · Azactam
- Belgium · Azactam
- Spain · Azactam
- Finland · Azactam
- United Kingdom (Northern Ireland) · Aztreonam Kent Pharma Uk, Aztreonam Kent Pharma Uk Ltd
- Ireland · Azactam
- Iceland · Cayston
- Liechtenstein · Cayston
- Luxembourg · Azactam
- Norway · Azactam, Cayston
- Portugal · Azactam
- Romania · Azactam
- Sweden · Azactam
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ddf8fe97-09f4-47c2-98bf-acf2e0495e26 GET /v1/drugs/ddf8fe97-09f4-47c2-98bf-acf2e0495e26?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "63918096",
"date_amm": "1987-07-08",
"type_amm": "Procédure nationale",
"numero_ue": null,
"substance": "AZTRÉONAM",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "poudre pour solution injectable pour perfusion",
"voies_administration": "intramusculaire;intraveineuse",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about aztreonam.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.